

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/132720 A1

(51) International Patent Classification:

C12N 5/0783 (2010.01) G01N 33/577 (2006.01)
C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2021/063245

(22) International Filing Date:

14 December 2021 (14.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/125,149 14 December 2020 (14.12.2020) US
63/265,086 07 December 2021 (07.12.2021) US

(71) Applicant: ALLOGENE THERAPEUTICS, INC.
[US/US]; 210 East Grand Avenue, South San Francisco,
California 94080 (US).

(72) Inventors: SEU, Lillian; 1551 Southgate Avenue, Unit
101, Daly City, California 94015 (US). GEE, Melanie L.; c/
o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South
San Francisco, California 94080 (US). BOWEN, Michael
A.; c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue,
South San Francisco, California 94108 (US).

(74) Agent: CHANG, Y. Elaine et al.; Allogene Therapeutics,
Inc., Legal IP, 210 East Grand Avenue, South San Francis-
co, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS AND REAGENTS FOR CHARACTERIZING CAR T CELLS FOR THERAPIES

(57) Abstract: Provided herein are methods, kits and reagents for analyzing attributes of engineered immune cells, such as CAR T cells. For example, provided herein are methods of determining the amount or percentage of residual TCRαβ+ CAR T cells in allogeneic CAR T cell drug product and characterizing other important attributes of CAR T cell drug product.

WO 2022/132720 A1